# US 2026/0232755 A1 · Method of treating patients with hepatorenal syndrome type 1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0232755 A1
- Document ID: US20260232755A1
- Status: Published application
- Kind: A1
- Application number: 19/559,498
- Filed: 2026-03-06
- Published: 2026-08-13
- Earliest claimed: 2014-10-24
- Assignees: Mallinckrodt Pharmaceuticals Ireland Limited
- Applicants: Mallinckrodt Pharmaceuticals Ireland Limited
- Inventors: Khurram Jamil; Stephen Chris Pappas; Peter Teuber
- Web page: https://patentgrep.com/patent/US20260232755A1

## CPC

- A61K 38/095: Oxytocins; Vasopressins; Related peptides
- A61B 5/0205: Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
- A61B 5/14542: {for measuring blood gases (A61B5/14551 takes precedence)}
- A61B 5/4839: {combined with drug delivery}
- A61B 5/4848: {Monitoring or testing the effects of treatment, e.g. of medication}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/38: Albumins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61M 27/002: {Implant devices for drainage of body fluids from one part of the body to another (intraocular A61F9/00781; middle ear A61F11/202)}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 13/12: of the kidneys
- G01N 15/10: Investigating individual particles
- G01N 33/4925: {measuring blood gas content, e.g. O2, CO2 , HCO3}
- G01N 2015/016: {White blood cells}
- G01N 2015/1024: {Counting particles by non-optical means}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A method of treating an adult patient with type 1 hepatorenal syndrome (HRS-1) may include administering a dose of terlipressin to the patient if the patient has a baseline model end stage liver disease (MELD) score<35, the patient has a serum creatinine (SCr)<5 mg/dl, the patient has an ACLF Grade<3, or a combination thereof and/or monitoring the patient's oxygenation level (SpO2) before and during treatment with the terlipressin.

## Claims

### Claim 1

A method of treating a patient suffering from type 1 hepatorenal syndrome (HRS-1) and having at least two of the following three criteria for Systemic Inflammatory Response Syndrome (SIRS):
a) a white blood cell count (WBC) less than 4,000 cells/mm3 or greater than 12,000 cells/mm3;
b) a heart rate of greater than 90 beats per minute (BPM); and
c) either a partial pressure of carbon dioxide in the blood (PaCO2)<32 mmHg or a blood bicarbonate (HCO3) level<23 mmol/L;
the method comprising administering a pharmaceutical composition comprising a dose of terlipressin to the patient for up to a maximum of 14 days;
wherein the patient who has at least two of the three criteria for SIRS treated with terlipressin has a higher rate of HRS reversal and transplant-free survival 90 days after treatment than a patient treated with terlipressin who does not have at least two of the three criteria for SIRS.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered by a slow bolus injection over 2 minutes.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered every 6 hours.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient's baseline serum creatinine (SCr) level is measured prior to administration of the pharmaceutical composition.

### Claim 5 (depends on 4)

The method of claim 4, wherein the pharmaceutical composition is administered for 3 days, and on day 4, the patient's serum SCr level is measured.

### Claim 6 (depends on 5)

The method of claim 5, wherein on day 4, the patient's SCr level decreased from the baseline SCr level, but by less than 30% from the baseline SCr value.

### Claim 7 (depends on 6)

The method of claim 6, wherein after obtaining the SCr level less than 30% lower than the baseline SCr level, the dose of terlipressin administered is increased.

### Claim 8 (depends on 5)

The method of claim 5, wherein on day 4, the patient's SCr level has not decreased from the baseline SCr level.

### Claim 9 (depends on 8)

The method of claim 8, wherein after obtaining the SCr level that has not decreased from the baseline SCr, administration of the pharmaceutical composition is discontinued.

### Claim 10 (depends on 5)

The method of claim 5, wherein on day 4, the patient's SCr level decreased from the baseline SCr level by more than 30% from the baseline SCr level.

### Claim 11 (depends on 10)

The method of claim 10, wherein after obtaining the SCr that has decreased from the baseline SCr level by more than 30%, administration of the pharmaceutical composition is continued.

### Claim 12

A method of improving the liver-transplant-free survival in a patient suffering from type 1 hepatorenal syndrome (HRS-1) and having at least two of the following three criteria for Systemic Inflammatory Response Syndrome (SIRS):
a) a white blood cell count (WBC) less than 4,000 cells/mm3 or greater than 12,000 cells/mm3;
b) a heart rate of greater than 90 beats per minute (BPM); and
c) either a partial pressure of carbon dioxide in the blood (PaCO2)<32 mmHg or a blood bicarbonate (HCO3) level<23 mmol/L;
the method comprising administering a pharmaceutical composition comprising a dose of terlipressin to the patient for up to a maximum of 14 days;
wherein the patient does not have sepsis;
wherein the patient treated with terlipressin who has at least two of the three criteria for SIRS and does not have sepsis has a higher rate of HRS reversal and transplant-free survival 90 days after treatment than a patient treated with terlipressin who does not have at least two of the three criteria for SIRS and has sepsis.

### Claim 13 (depends on 12)

The method of claim 12, wherein the patient has three of the criteria for SIRS.

### Claim 14 (depends on 12)

The method of claim 12, wherein the dose of terlipressin is 0.85 mg.

### Claim 15 (depends on 12)

The method of claim 12, wherein the dose of terlipressin is 1.7 mg.

### Claim 16 (depends on 12)

The method of claim 12, wherein the patent is also administered albumin.

### Claim 17 (depends on 16)

The method of claim 16, wherein the patient is administered up to a maximum of 100 g of albumin per day of treatment with the pharmaceutical composition.

### Claim 18 (depends on 12)

The method of claim 12, wherein the patient does not have uncontrolled infection.

### Claim 19 (depends on 12)

The method of claim 12, wherein the patient does not have septic shock.

### Claim 20

A method of increasing the 90-day survival rate in a patient who has type-1 hepatorenal syndrome and at least two of the following three criteria for Systemic Inflammatory Response Syndrome (SIRS):
a) a white blood cell count (WBC) less than 4,000 cells/mm3 or greater than 12,000 cells/mm3;
b) a heart rate of greater than 90 beats per minute (BPM); and
c) either a partial pressure of carbon dioxide in the blood (PaCO2)<32 mmHg or a blood bicarbonate (HCO3) level<23 mmol/L;
the method comprising administering a pharmaceutical composition comprising a dose of terlipressin to the patient until the patient experiences an ischemic event or up to a maximum of 14 days;
wherein the patient treated with terlipressin who has at least two of the three criteria for SIRS has a higher 90-day survival rate than a patient treated with a placebo who has at least two of the three criteria for SIRS;
wherein the placebo comprises mannitol.

### Claim 21 (depends on 20)

The method of claim 20, wherein the patient does not have sepsis.

### Claim 22 (depends on 20)

The method of claim 20, wherein the patient does not have uncontrolled infection.

### Claim 23 (depends on 20)

The method of claim 20, wherein the patient does not have septic shock.

### Claim 24 (depends on 20)

The method of claim 20, wherein the ischemic event is cardiac ischemia.

### Claim 25 (depends on 20)

The method of claim 20, wherein the ischemic event is gastrointestinal ischemia.

### Claim 26

A method of treating a patient suffering from type 1 hepatorenal syndrome (HRS-1) and having at least two of the following three criteria for Systemic Inflammatory Response Syndrome (SIRS):
a. a white blood cell count (WBC) less than 4,000 cells/mm3 or greater than 12,000 cells/mm3;
b. a heart rate of greater than 90 beats per minute (BPM); and
c. either a partial pressure of carbon dioxide in the blood (PaCO2)<32 mmHg or a blood bicarbonate (HCO3) level<23 mmol/L;
the method comprising: (i) measuring a baseline serum creatinine (SCr) level in the patient; (ii) administering a pharmaceutical composition comprising an initial dose of terlipressin to the patient for an initial 1 to 4 days; (iii) measuring a SCr level in the patient on day 4 after administration of the pharmaceutical composition; (iv) adjusting the initial dose of terlipressin administered on day 4 based on the SCr level obtained in the patient on day 4; and (v) continuing administration of the pharmaceutical composition for up to a maximum of 14 days.

### Claim 27 (depends on 26)

The method of claim 26, wherein the initial dose of terlipressin in 0.85 mg.

### Claim 28 (depends on 26)

The method of claim 26, wherein on day 4, the patient's SCr level decreased from the baseline SCr level, but by less than 30% from the baseline SCr level, and the initial dose of terlipressin administered is increased.

### Claim 29 (depends on 28)

The method of claim 28, where the increased dose of terlipressin is 1.7 mg.

### Claim 30 (depends on 27)

The method of claim 27, wherein on day 4, the SCr level decreased from the baseline SCr level by more than 30%, and the initial dose of terlipressin administered is maintained.
